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ttp://dx.doi.org/10.1016/j.jmoldx.2013.06.005The photostability and narrow emission spectra of nonorganic quantum dot ﬂuorophores make them
desirable detection methods for ultrasensitive and multiplexing in situ hybridization applications to
identify genetic aberrances in morphologically preserved clinical tissue specimens. However, robustness
and reliability have not been fully investigated for quantum dot ﬂuorophores in situ hybridization
applications. We demonstrate the feasibility of an automated multiplexing four-color quantum dot
ﬂuorophores in situ hybridization assay comprised of four genomic probes each labeled with unique
haptens, four anti-hapten antibodies each conjugated with quantum dot ﬂuorophores with distinct
emission spectrum, protocols for their use on a fully automated tissue staining platform, and direct
observation of multiple signals using conventional ﬁlter-based ﬂuorescent microscopy. This assay is
successfully applied to the simultaneous detection of ERG3p, ERG5p, PTEN, and CEN10 genes in formalin-
ﬁxed, parafﬁn-embedded prostate tissues on BenchMark ULTRA instruments. There were 386 slides from
10 prostatectomy cases stained on 13 on these instruments. These 10 cases consisted of benign
prostate and prostate cancer; the cancer cases were either positive or negative for ERG rearrangement
and/or contained PTEN deletion. There were 350 (91%) slides appropriately stained for all four targets.
The staining results accurately identiﬁed the ERG and PTEN status for all 10 cases. This approach is
expected to enable multiplexing in situ detection of molecular biomarkers in routinely processed human
clinical specimens. (J Mol Diagn 2013, 15: 754e764; http://dx.doi.org/10.1016/j.jmoldx.2013.06.005)Disclosure: All authors are full- or part-time employees of Ventana
Medical Systems, Inc.Fluorescence in situ hybridization (FISH) technique pro-
vides a direct visualization of the spatial location of speciﬁc
nucleic acid sequences at a particular cellular site in tissue
sections.1 Such morphological and topological information
has been invaluable for clinical evaluation of human generic
aberrances, gene expression levels, and viral infections, etc.
Although conventional FISH uses various organic ﬂuo-
rophores that allow simultaneous visualization of multiple
targets in distinct colors, it faces several limitations in-
cluding a limited number of available ﬂuorochromes, broad
emission spectra, and rapid photobleaching. Although
chromogenic in situ hybridization has its advantage of
simultaneously viewing as many as two brightﬁeld signals
and tissue morphology, it is largely limited to visualizing
multiple targets and assessing colocalization.stigative Pathology
.Quantum dots (QDs) are semiconductor nanocrystals that
represent novel ﬂuorophores.2 They have narrow emission
spectra that facilitate the simultaneous detection of multiple
cellular targets. They are ultra-bright ﬂuorophores that are
not as prone to photobleaching as organic ﬂuorophores,
which is advantageous to generate enhanced signal-to-noise
ratio staining. Given these remarkable optical properties,
QDs have recently emerged as a potentially ideal material
for use in FISH.3
QDs were applied to detect nucleic acids both indirectly
(ie, biotin-labeled probes with QD-conjugated streptavidin)
and directly (ie, synthesis of QD-labeled short nucleotide
Automated Four-Color ERG/PTEN QD FISHprobes). Single QD FISH application was achieved on
human metaphase,4 mouse,5 plant chromosomes,6 Escher-
ichia coli,7 Epstein-Barr virus,8 and human papillomavirus.9
Moreover, biotinylated Her2 DNA probe with streptavidin-
conjugated QD605 was applied to detect low copy HER2
gene in human lymphocytes and HER2 gene-ampliﬁcation
in SK-BR-3 breast cancer cells.4 Similar observation on
gene ampliﬁcation was made on lung cancer specimens with
the application of QD-conjugated genomic DNA of genes.10
The ﬁrst duplex QDs FISH was used to detect centromere-
associated satellite sequences on cultured cell lines with
oligonucleotides that directly attach QD592 and QD655.11
Furthermore, several triplex QD-FISH assays were devel-
oped as quantitative tools to measure gene expression
proﬁle. Chan et al5 reported a multiplex cellular detection of
mRNAs in mouse tissue. Two oligonucleotide probes were
labeled with QD ﬂuorophores QD565 and QD605, and two
other probes labeled with two organic ﬂuorophores Alexa
488 and Alexa 568 (Alexa Fluor, Life Technologies, Grand
Island, NY). The multispectral simultaneous detection of up
to four different mRNA targets in the same cells was ach-
ieved with a confocal microscopy. Byers et al12 presented
a triplex QD FISH and immunohistochemistry (IHC)
approach that enables simultaneous measurement of two
gene expression proﬁles and one cell lineage marker on
routinely processed tissue samples. Two oligonucleotide
probes labeled with biotin or digoxigenin (DIG) were
detected with respective anti-hapten antibodies conjugated
with QD525 or QD605, whereas the cell lineage marker was
revealed by an antibody conjugated with QD655. Tholouli
et al13 described a triplex QD-FISH assay using two sets of
three oligonucleotide probes each that was conjugated to
QD605, QD655, and QD705, respectively. This assay was
used for six gene expression proﬁling in an acute myeloid
leukemia tissue microarray. With the aforementioned efforts
of FISH applications, QD FISH has been reported with
reliability and/or reproducibility issues.14,15 The intermittent
experimental success was partially explained as the
phenomenon of steric hindrance and accessibility issue
owing to the large-size nanocrystals.4,5,6,16
Here we explore the use of QDs in development of an
automated multiplexing in situ hybridization (ISH) assay for
detection of ERG and PTEN gene status in routine prepared
prostate tissue specimens. ERG rearrangement and PTEN
deletion are two of the most common genomic events in
human prostate cancer.17e19 Overexpression of the ERG
protein caused by ERG rearrangement has been frequently
associated withmore aggressive prostate cancers and a poorer
prognosis. PTEN genomic deletion and absence of PTEN
expression are associated with unfavorable clinical outcome
measures. Moreover, according to recent studies,18,19 it is
suggested that PTEN loss and ERG genetic rearrangements
are concomitant events in human prostate cancer. Han et al18
have demonstrated the importance of localization of PTEN
and ERG genes that make up their signatures in cancer foci,
high-grade prostatic intraepithelial neoplasia adjacent toThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcancer, high-grade prostatic intraepithelial neoplasia away
from cancer, andmetastatic sites. Therefore, a genericmethod
for simultaneous visualization of multiple genes will be crit-
ical for the investigation of spatial localization of gene
signatures in tumor cells and their neighbors, such as immune
and stromal cells as well. Multiplexing ISH assay on a single
slide will also allowmore judicious use of minimally invasive
biopsy techniques favoring comfort of the patient. The use of
such molecular biomarkers in routine clinical practice is
presently limited by the technical difﬁculty of multivariate
in situ hybridization (eg, detection of four targets simulta-
neously). We developed a robust automated four-color multi-
plexingQDs ISH assay to simultaneously detect these clinically
important cancer biomarkers.WeproducedDIG-labeled,DNP-
labeled, thiazole sulfonamide-labeled, and NP-labeled DNA
probes and used four anti-hapten antibodies conjugated to
QD525, QD565, QD605, and QD655 to visualize the probes.
The speciﬁc binding of the probes to their chromosome loca-
tionswere veriﬁedbymetaphase spreads.Wedemonstrated that
tissue pretreatment condition is critical for QD ISH assay. We
tested this multiplexing QD ISH assay on 386 slides with tissue
sections from 10 prostate specimens across using 13 Bench-
Mark ULTRA instruments (Ventana Medical Systems, Inc.,
Tucson, AZ). The 10 cases consisted of eight benign prostate
and two prostate cancer specimens. Our experiments show that
350 (91%) of the slides were successfully stained for all four
targets. Furthermore, the staining results accurately identiﬁed
the ERG and PTEN status for all 10 cases.
Materials and Methods
Tissue Samples
Ten prostatectomy tissue samples were obtained from
a tissue specimen archive maintained at Ventana Medical
Systems, Inc. Samples were redundant clinical specimens
that had been de-identiﬁed and unlinked from patient
information, and therefore, patient informed consent was not
required (US Food and Drug Administration. http://www.
fda.gov/downloads/MedicalDevices/DeviceRegulationand
Guidance/GuidanceDocuments/ucm071265.pdf, last accessed
September 12, 2013). One hundred serial sections (approxi-
mately 4 micron) were cut for each sample, and cuts 1 and 100
were stained with H&E. Cases were included if both cuts had
adequate epithelium and consistent pathological interpretation.
Eight cases were diagnosed as benign tissues, whereas two
cases were prostate cancer. Thirty-nine slides were ﬁrst
randomly selected from each of the 10 prostatectomy speci-
mens, with three slides from each of the 39 slides for the 10
cases that were then randomly selected and distributed onto the
30-slide positions of 13 BenchMark ULTRA instruments.
ERG3p, ERG5p, PTEN, and CEN10 Probes
ERG3p and ERG5p probes were developed to assess the
rearrangements of the ERG gene loci. They were designed755
Figure 1 Schematic illustration of the simultaneous detection of four molecular targets using the four-color multiplexing QD ﬂuorophores ISH assay. Step
1: Tissue specimens are pretreated for optimal nuclear permeabilization. Step 2: DIG-labeled, DNP-labeled, TS sulfonamide-labeled, and NP-labeled DNA probes
hybridize to their respective molecular targets. Four anti-hapten antibodies that are conjugated to QD525, QD565, QD605, and QD655 detect the probes.
Zhang et alto target the neighboring centromeric region (317 kb) and
telomeric region (370 kb) of the ERG gene, which ﬂank the
known breakpoint region of the ERG gene.20 The repeat-
depleted probe production approach, as previously de-
scribed,21,22 was used to generate the two probes. ERG5p
probe was labeled by nick translation using dUTP conju-
gated to DIG (Roche Applied Sciences, Indianapolis, IN)
(1:2 ratio of DIG-dUTP: dUTP), whereas ERG3p probe was
labeled using dCTP conjugated to 2,4 DNP (Ventana
Medical Systems, Inc.), and only DNP-dCTP was used. The
PTEN probe was designed to target a 765 kb region of the
PTEN location (10q23.31)23,24 and was generated by the
same technology as the ERG probes.21,22 The PTEN probe
was labeled by nick translation using dUTP conjugated to
thiazole sulfonamide (TS; in development) (3:1 ratio of
TS-dUTP: dUTP). A chromosome 10-speciﬁc pA10RP8
plasmid (ATCC, Manassas, VA) containing the centromeric
region was used to generate the CEN10 probe. The CEN10
probe was labeled by nick translation using dUTP conju-
gated NP (in development) (3:1 ratio of NP-dUTP: dUTP).
The labeled probes were enriched in sizes between 100 and
500 bp by nick translation reaction. The ERG3p-DNP-
labeled probe (30 mg/mL) and ERG5p-DIG-labeled probe
(30 mg/mL each) were formulated with 3 mg/mL human
placental DNA in a formamide-based buffer in a dispenser.
The PTEN-TS-labeled probe and CEN10-NP-labeled probe
(20 mg/mL each) were formulated the same way in another
dispenser.
QD-Conjugated Antibodies
A rat monoclonal anti-DNP (Clone 1C7-1C7; Ventana
Medical Systems, Inc.) was conjugated to QD655. A mouse
anti-DIG monoclonal antibody (Clone 1-171-256; Roche
Applied Sciences) was conjugated to QD565. A mouse anti-
TS monoclonal antibody (Clone 13A06-01E11; Ventana
Medical Systems, Inc.) was conjugated to QD605. A mouse756anti-NP monoclonal antibody (Clone 27F09-02F08; Ventana
Medical Systems, Inc.) was conjugated to QD525. All QDs
were custom-made by Life Technologies (Carlsbad, CA). All
antibody conjugations were conducted using 30 PEGylated
QD (Life Technologies) and puriﬁed monoclonal anti-
bodies.25 The QD-conjugated antibodies (25 nm each) were
mixed in a borate buffer based diluent in a dispenser.
Automated Four-Color ERG/PTEN QD in Situ
Hybridization
The automated four-color ERG/PTEN QD ISH assay was
performed using BenchMark ULTRA instruments. The
schematic diagram of assay conﬁguration is illustrated in
Figure 1. Formalin-ﬁxed, parafﬁn-embedded tissue sections
on slides were deparafﬁnized using a mild detergent (EZ-
Prep; Ventana Medical Systems, Inc.) at 69C for 72
minutes. Tissue pretreatment was conducted with a combi-
nation of heat- and proteolytic-induced epitope retrieval
steps. First, tissue sections were incubated in a basic Tris
buffer-based solution (CC1; Ventana Medical Systems, Inc.)
at 90C for 92 minutes. Next, tissue sections were incubated
in an acidic citrate buffer-based solution (CC2; Ventana
Medical Systems, Inc.) at 82C for 36 minutes. Last, tissue
sections were treated with a serine protease (Protease 3;
Ventana Medical Systems, Inc.) at 37C for 28 minutes.
After pretreatment, all four probes were added to the slides.
Genomic DNA and the probes were denatured online at
85C for 8 minutes, followed by probe hybridization for 6
hours at 44C in Hybrizol (Ventana Medical Systems, Inc.).
After three stringency washes with SSC (Ventana Medical
Systems, Inc.) at 72C for 8 minutes each, the four QD-
conjugated antibodies mixture was added and incubated at
37C for 60 minutes. The slides were rinsed three times with
reaction buffer (Ventana Medical Systems, Inc.), DAPI
(Ventana Medical Systems, Inc.) was then applied online
to counterstain nuclei for imaging. The stained slides werejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Filter Conﬁgurations
Position Filter name
Emission
wavelength (nm) Filter ID No.
1 DAPI þ 565 þ 655 565  4/655  4 245994
2 DAPI þ 655 655  4 245998
3 565 565  4 129205
5 605 605  4 120802
6 DAPI þ 525 525  4 246850
Figure 2 Examples of nuclei classiﬁed as negative or positive for ERG
gene rearrangement. A nucleus with: one pair of adjacent red and green
signals and fused yellow signal (A); two pairs of adjacent red and green
signals (B); one pair of adjacent red and green signals and a single green
signal without a corresponding red signal (C); one pair of adjacent red and
green signals and one pair of broken apart red and green signals (D); two
pairs of broken apart red and green signals (E); one pair of adjacent red and
green signals and a single red signal without a corresponding green signal
(F); one pair of adjacent red and green signals, one pair of broken apart red
and green signals, and a single red signal without a corresponding green
signal (G). The nuclei shown in AeC are all considered negative and
positive in DeG for ERG gene rearrangement.
Automated Four-Color ERG/PTEN QD FISHcover slipped in Cytoseal60 (Richard-Allan Scientiﬁc,
Kalamazoo, MI).
The slides of metaphase spreads were stained with ERG/
PTEN four-color QD ISH on a BenchMark ULTRA
instrument using a modiﬁed procedure (by omitting the
deparafﬁnization and tissue pretreatment steps).
QD ISH Slide Review, Image Capture, and Analysis
A Zeiss ﬂuorescent microscope (Carl Zeiss, Jena, Germany)
with appropriate ﬁlters was used for slide review. Custom-
made emission ﬁlter sets (Chroma Technology Corp.,
Bellows Falls, VT) used in the study are listed in Table 1.
The excitation wavelength for all of the dots is 355 to 405
nm. All emission ﬁlter sets possessed the same excitation
ﬁlter bandwidth. Monochrome images were captured using
a Spectral Imaging acquisition system (ASI; Applied
Spectral Imaging, Carlsbad, CA), and images were taken
using a SPOT CCD microscope digital camera (SN#
252371; Diagnostic Instruments, Inc., Sterling Heights, MI).
The layers of individual monochrome FISH signal were
colorized and merged to provide overlay images for visu-
alization of relative probe localizations using ImageJ
version 1.47 (NIH, Bethesda, MD).
Analytical Slide Scoring Criteria
A board-certiﬁed pathologist (P.B.) with experience on
interpreting the four-color ERG/PTENQD ISH stained slides
reviewed and scored the slides. Each slide was scored for
signal intensity, background, and coverage. The analytical
slide scoring criteria (Table 2) are described as “Acceptable”
or “Not Acceptable” staining. The “Acceptable” or “Not
Acceptable” criteria correspond to the capability of whether
the ERG (or QD565 and QD655) or the PTEN/CEN10Table 2 The Analytical Slide Scoring Criteria
Acceptable
Signal
intensity
3, Strong bright signal, viewable at 200, easy to
score under the magnification of 400
2, Moderate bright signal, viewable at 400, easy
to score under the magniﬁcation of 600
Background 3, No background staining
2, Low background staining that does not interfere
with signal scoring
Overall coverage 4: 70%; 3:50%e70% 2: 25%50% (discretio
The Journal of Molecular Diagnostics - jmd.amjpathol.org(QD525 and QD605) pairs of signals are enumerable in 50
cells on a slide. The scoring criteria were developed and used
as a stringent analytical tool for the purpose of assay opti-
mization. Further studies will be carried out to develop cut-
off values that are clinically relevant.
Signal Enumeration and Cell Classiﬁcation of ERG
The signals were enumerated within the nuclear boundary of
each selected epithelial cell, according to the guidelines
provided in Figure 2 and Table 3. Nuclei containing signals
of only one color should not be enumerated.
A cell is considered negative for ERG gene rearrangement
when either of the following occurs: When only fused signals
and/or pair(s) of adjacent red (ERG3p/QD655) and green
(ERG5p/QD565) signals are present in the nucleus (Figure 2,
A and B). Fused signals are overlapping red and green signals
and appear as yellow. A pair of adjacent red and green signals
is deﬁned as a pair of a red signal and a green signal that are
less than two signal diameters apart. Alternatively, in addi-
tion to fused signals and/or adjacent red and green signals,
when only one or more single green signals are present
without corresponding red signal(s) (Figure 2C).Not acceptable
1, Low brightness, signal difficult to score under the
magnification of 600
0, No visible signal under the magnification of 600
1, High background staining that interferes with signal scoring
0, Severe background staining
n for accceptable/not acceptable) 1: 10%e25%; 0: 0%e10%
757
Figure 3 A representative image of a normal metaphase spread stained
with ERG/PTEN four-color QD ﬂuorophores ISH on a BenchMark ULTRA
instrument (Ventana Medical Systems, Inc.). Two pairs of red signals rep-
resenting ERG3p are shown adjacent to the two pair of green signals rep-
resenting ERG5p. Two pairs of pink and blue signals representing PTEN and
CEN10 are located on another chromosome. No extra signals of ERG3p,
ERG5p, PTEN, or CEN10 probes were observed on other chromosomes.
Table 3 Classiﬁcation of Cells as Positive or Negative for ERG
Gene Rearrangement
Signal proﬁle
as shown in
Figure 2
Number of
adjacent
or fused
signals
Number of
single red
signals
Number
of single
green
signals
Cell
classiﬁcation
A, B 1 0 0 Negative
C 1 0 1 Negative
DeG 0 1 1 Positive
F 1 1 0 Positive
Zhang et alA cell is considered positive for ERG gene rearrangement
when one of the following occurs: At least one pair of broken
apart red and green signals is present in the nucleus (Figure 2,
D and E). A pair of broken apart red and green signals is
deﬁned as a pair made of a red signal and a green signal that
are two or more signal diameters apart. Alternatively, in
addition to fused and/or adjacent red and green signals, when
one single red signal or more single red signals are present
without corresponding green signal(s) (Figure 2F). Also,
alternatively, when broken apart signals and single red
signal(s) are present in the same nucleus (Figure 2G).
For each slide, 50 cells were enumerated and the per-
centage of cells positive for ERG gene rearrangement was
calculated. The 50 cells were enumerated in an area with
acceptable staining of normal epithelium or carcinoma, and
adjacent acceptable staining of internal control cells, such as
stromal cells. Only cells containing at least one signal of
QD525, QD565, and QD655 each were counted. The same
area was marked on subsequent slides using the 5 objec-
tive, and enumeration was performed here.
Signal Enumeration of PTEN and CEN10
For each slide, the number of PTEN and CEN10 signals was
enumerated in 50 nuclei. The PTEN and CEN10 signal ratio
was calculated. For normal tissue, the ratio of PTEN and
CEN10 is expected to be close to 1.
Statistical Analysis
Differences in signal intensity and staining coverage
between the two pretreatment conditions were assessed by
two-sample t-test using Minitab 16.2.0 Statistical Software
(Minitab, Inc., State College, PA).
Results
Veriﬁcation of Speciﬁcity of the ERG3p, ERG5p, PTEN,
and CEN10 Probes
To verify that ERG3p, ERG5p, PTEN, and CEN10 probes
speciﬁcally bind to their target chromosomes, we demon-
strated co-localization of ERG3p and ERG5p with Abbott/
Vysis LSP21 probe (Abbott Molecular, Des Plaines, IL) to
the same chromosome (chromosome 21), and colocalization758of PTEN and CEN10 probes with Abbott/Vysis CEP10
(Abbott Molecular) to the same chromosome (chromosome
10). No extra signals of ERG3p, ERG5p, PTEN, or CEN10
were observed on other chromosomes (data not shown).
Figure 3 shows a representative image of a normal meta-
phase spread stained with ERG/PTEN four-color QD ISH
on a BenchMark ULTRA instrument. ERG3p-DNPe
labeled probe and ERG5p-DIGelabeled probe were co-
hybridized on the same chromosome, and detected with
QD655 (red) and QD565 (green). Two pairs of red signals
representing ERG3p were shown adjacent to the two pair of
green signals representing ERG5p. The PTEN-TSelabeled
probe and the CEN10-NPelabeled probe were co-
hybridized on another chromosome, and detected with
QD605 (pink) and QD525 (blue), respectively. No extra
signals of ERG3p, ERG5p, PTEN, or CEN10 probes were
observed on other chromosomes.Efﬁcient Nuclear Permeabilization Is Critical for
a Robust Four-Color ERG/PTEN QD ISH Assay
We initially observed the lack of reliability and/or repro-
ducibility of the four-color ERG/PTEN QD ISH assay
similar to as others describing QD ISH assays.14,15 The
intermittent experimental success was manifested as slide-
to-slide and/or day-to-day variations. On average, the four-jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Comparison of staining performance
between condition 1 (CC2 and protease 3) and
condition 2 (CC1, CC2, and protease 3) for tissue
pretreatment. A: QD525 intensity. B: QD565
intensity. C: QD605 intensity. D: QD655 intensity.
Fifteen slides with condition 1 result in a wide
range of signal intensity and staining coverage, in
which none was acceptable for all four targets.
Fifteen slides with condition 2 result in consis-
tently acceptable signal intensity (2) and stain-
ing coverage (>50%) for all four targets.
Automated Four-Color ERG/PTEN QD FISHcolor ERG/PTEN QD ISH assay was <50% of the time
based on the analytical scoring criteria (Table 2). In attempts
to improve the efﬁcacy and reliability of the four-color
ERG/PTEN QD ISH assay, the assay conditions were
systematically investigated, including various pretreatment
conditions (for nuclear permeabilization), probe hybridiza-
tion conditions (eg, probe concentration, denaturation
temperature and time, stringency wash conditions, etc), and
QD-conjugated antibody detection conditions (eg, antibody
concentration, incubation time, blocking steps, etc). We
found that although optimization of probe hybridization or
QD detection conditions helps, pretreatment condition for
nuclear permeabilization was critical for reliable and
reproducible QD ISH staining. We compared two pretreat-
ment conditions: CC2 at 82C for 36 minutes followed by
protease 3 at 37C for 28 minutes, and CC1 at 90C for 92
minutes followed by CC2 at 82C for 36 minutes and then
protease 3 at 37C for 28 minutes (as described in Materials
and Methods). Thirty consecutive 4 mm sections were
prepared from a prostatectomy case (VR-209-11-3), and
were stained with the four-color ERG/PTEN QD ISH on
a BenchMark ULTRA instrument. One half of the slides
was treated with condition 1 and the other half was treated
with condition 2. As shown is Figure 4, the 15 slides treated
with CC2 and protease 3 (condition 1) resulted in a wide
range of signal intensity and staining coverage, in which
none was acceptable for all of the four targets. In contrast,
the 15 slides treated with CC1 in addition to CC2 and
protease 3 (condition 2) resulted in consistently acceptable
signal intensity (2) and staining coverage (>50%) for all
four targets on the 15 slides. Background and tissue
morphology were acceptable for all 30 slides and were
comparable between the two pretreatment conditions (data
not shown). Table 4 compares the average signal intensity
and staining coverage for each QD staining between the two
pretreatment conditions. These results indicate that theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgpretreatment with CC2 and protease 3 was not sufﬁcient for
a reliable four-color ERG/PTEN QD ISH assay. Addition of
CC1 to CC2 and protease 3 pretreatment signiﬁcantly
improved QD ISH staining. It not only resulted in greater
average signal intensity and staining coverage for all four
targets but also in less variances among the replicate slides.
Evaluation of Four-Color ERG/PTEN QD ISH Assay
Performance on Multiple BenchMark ULTRA
Instruments
The four-color ERG/PTEN QD ISH assay with the im-
proved pretreatment condition (CC1 at 90C for 92 minutes
followed by CC2 at 82C for 36 minutes and then protease 3
at 37C for 28 minutes) was evaluated on 13 BenchMark
ULTRA instruments. A total of 389 slides from 10 prosta-
tectomy specimens were stained. The 10 specimens con-
sisted of eight benign prostate tissues and two prostate
cancer cases. Triplicate slides of each case were placed on
each instrument (total 30 slides per instrument). Of 389
slides, there were 386 evaluated for staining performance
(signal intensity, background, staining coverage, and tissue
morphology, according to the analytical scoring criteria
shown in Table 2). Three slides were excluded from the
analyses due to nonassay related causes. Overall, 91% (350
of 386) of the slides resulted in acceptable staining for both
ERG3p and 5p and PTEN/CEN10. There were 36 slides that
failed from which 28 failures were due to QD655 high
background and eight failures were due to weak or no signal
(Supplemental Table S1).
The 350 slides with acceptable QD ISH staining were
evaluated for ERG and PTEN gene status. Two hundred and
eighty slides from the eight benign prostate cases and 70
slides from the two prostate cancer cases were used. Wild-
type ERG (1 to 2 fused signals per nucleus), PTEN (1 to
2 signals per nucleus), and CEN10 (1 to 2 signals) were759
Table 4 Signal Intensity and Staining Coverage for the Four Targets Under the Two Pretreatment Conditions
Condition N
525 Signal intensity 565 Signal intensity 605 Signal intensity 655 Signal intensity
No. pass/failMean SD Mean SD Mean SD Mean SD
2 15 2.3 0.2 2.5 0.1 2.4 0.2 2.5 0.1 15
1 15 0.5 0.7 0.7 0.9 0.1 0.5 0.3 0.5 0
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Condition N
525 Signal coverage 565 Signal coverage 605 Signal coverage 655 Signal coverage
No. pass/failMean SD Mean SD Mean SD Mean SD
2 15 3.2 (50%e70%) 0.8 3.8 (50%e70%) 0.4 3.6 (50%e70%) 0.8 3.7 (50%e70%) 0.5 15
1 15 0.3 (<25%) 0.5 0.5 (<25%) 0.6 0.1 (<25%) 0.5 0.4 (<25%) 0.6 0
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
P values determined using two-sample t-test analysis.
SD, standard deviation.
Zhang et alconsistently observed in all 280 slides from the 8 benign
prostate cases. Representative images for a benign prostate
case are shown in Figure 5.
Of the two prostate cancer cases, ERG break-apart and
PTEN deletion were consistently observed in the 36 slides
of case #VMSI106-C21D, whereas ERG break-apart and
PTEN normal status were consistently observed in the 34
slides of case #161168T21D. The representative images for
VMSI-106-C21D are shown in Figure 6.Detection of ERG and PTEN Gene Status
After the overall evaluation of the 350 slides, 19 were
randomly selected from two benign and two prostate cancer
cases for signal enumeration to determine ERG and PTEN
gene status. They were stained on three BenchMark
ULTRA instruments over three different days. For each
slide, 50 nuclei were enumerated for ERG3p, ERG5p,Figure 5 Representative images of a benign prostate case stained with
the ERG/PTEN four-color QD ﬂuorophores ISH assay. H&E staining of
a normal gland (A), ERG3p, ERG5p, PTEN, and CEN10 four-color ERG/PTEN QD
ISH staining (B), two-color image of ERG3p (red) and ERG5p (green) (C),
and two-color image of PTEN (pink) and CEN10 (blue) ISH staining (D).
760PTEN, and CEN10 signals using a conventional ﬂuorescent
microscope. A triple-band ﬁlter (DAPI þ 565 þ 655),
a single-band ﬁlter (565), and a dual-band ﬁlter (DAPI þ
655) were used for ERG signal enumeration. PTEN and
CEN10 signals were enumerated using single-band ﬁlter
(605) and dual-band ﬁlter (DAPI þ 525), respectively. The
number of ERG3p and ERG5p fused signals, ERG3p single
signals and ERG5p single signals were enumerated in each
nucleus, and ERG gene status was classiﬁed for each of the
50 cells (Figure 2 and Table 3). Percent nuclei with ERG
break-apart were calculated for each slide. The ratios of
PTEN and CEN10 signals were calculated for 50 nuclei per
slide. The data in Table 5 demonstrates that the staining
results of ERG and PTEN gene status are reproducible for
the four cases stained in multiple days across three ULTRA
instruments. For case VR-62-11-24 (benign prostate tissue),
the percentages of ERG rearrangement-positive cells are
between 0% and 6%, and the ratios of PTEN and CEN10
signals range between 0.94 and 1.0 for the ﬁve slides. For
case 161168T21D (prostate cancer), the percentages of ERG
rearrangement-positive cells range between 78% and 90%,
and the ratios of PTEN and CEN10 signals range between
0.8 and 0.9 for the four slides. For case VMSI106-C21D
(prostate cancer), the percentages of ERG rearrangement-
positive cells range between 74% and 88%, and the ratios
of PTEN and CEN10 signals are zero for the six slides. For
case VR11-330-4 (benign prostate tissue), the percentages
of ERG rearrangement-positive cells range between 0% and
2.0%, and the ratios of PTEN and CEN10 signals range
between 0.9 and 1.1 for the three slides.Discussion
A pervasive trend in modern pathology is to explore the
origins of disease through characterization of complicated
genetic abnormalities.26 We envision that the ultrasensitive
and high-throughput multiplexing ISH technology will
serve this unmet medical need for rapid and reliable detec-
tion of multibiomolecules on the single cell level in
routinely processed clinical tissues. Herein, we describe forjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 6 Representative images of a prostate cancer case (VMSI-106-
C21D) stained with the ERG/PTEN four-color QD ﬂuorophores ISH assay.
A: H&E staining. B: ERG3p, ERG5p, PTEN, and CEN10 4 QD ISH staining. C:
Two-color image of ERG3p and ERG5p ISH staining. Single ERG 3p (red) and
ERG5p (green) signals were observed in the nuclei of the epithelial cells.
DeF: Two-color image of PTEN (pink) and CEN10 (blue) ISH staining in
both tumor and stromal tissue area (D); two-color image of PTEN (pink) and
CEN10 (blue) ISH staining in tumor area (E); and two-color image of PTEN
(pink) and CEN10 (blue) ISH staining in stromal area (F). E and F closer
views of the PTEN and CEN10 signals from the tumor area (E) or the
adjacent stromal tissue area (F) marked in D. E: PTEN signal (pink) is
missing in tumor cells, only CEN10 signals (blue) are present. F: The PTEN
staining at the stromal area serves as the internal control. Both PTEN
signals (pink) and CEN10 signals (blue) are present in the stromal area.
Automated Four-Color ERG/PTEN QD FISHthe ﬁrst time an automated multiplexing QD ISH method-
ology for simultaneous detection of four molecular targets.
The robustness of this assay (91% pass rate) may alleviate,
if not eliminate, the concerns of the unreliable nature of QDs
for FISH.14,15 In addition, the reliable and reproducible
interpretation of the replicate slides demonstrates the feasi-
bility of using the assay in the clinical application.The Journal of Molecular Diagnostics - jmd.amjpathol.orgSeveral features distinguish this assay from other QD ISH
applications previously described in the literature. First, this
assay adopts an indirect QD detection scheme as the QDs are
labeled with antibodies, but not on probes directly. This
scheme improves hybridization efﬁciency by hapten-labeled
probes, contrary to those of QD-labeled probes that may
cause issues of steric hindrance because of the QD size. It
also avoids incubation of QDs at high temperature, which
affects the stability of QDs. Various efforts have been made
to address the possible steric hindrance of the direct QD
detection. Ma et al16 tried to keep the oligonucleotide probe
further away from the QD surface using a homopolymer of
thymidine sequence. The modiﬁcation of the hydrodynamic
diameter of the probes was claimed small enough to penetrate
into maize chromosomes. Choi et al27 coupled the DNA
oligonucleotides via a 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride molecule and used it with
polymer-coated QDs. This effort allowed the visualization of
gene targets in Drosophila. Chan et al5 raised the issue of the
multiple streptavidin sites on the QD molecule that could
interfere with hybridization efﬁciency. They use biocytin,
a competitive blocker of streptavidin, in the labeling process
of oligonucleotide probes. On the other hand, Ioannou and
Grifﬁn15 reported their repeated attempts using direct
conjugation strategy of DNA to QDs without exception
ended in failure. Our indirect QD-labeling enabled an alter-
native approach to achieve good hybridization efﬁciency.
Next, this assay features four genomic probes that are nick
translation-labeled with four distinct haptens. These haptens
are then detected with anti-hapten antibodies conjugated with
four QDs that are 40 nm apart in wavelengths. Unlike the
widely used DNP and DIG, two new haptens (NP and TS)
lacked information on optimal labeling conditions, func-
tionality of the NP- and TS-labeled probe on hybridization, as
well as the latter immunological detection. With this work,
we empirically developed the optimal nick translation
methods for NP- and TS-modiﬁed nucleotides. Functional
staining results and hapten incorporation measurements (data
not shown) conﬁrmed that: i) the 3:1 ratio of hapten-labeled
dUTP versus native dUTP offers optimal hybridization efﬁ-
ciency, ii) this labeling method allows optimal enzymatic
incorporation of the modiﬁed nucleotide into the probes, and
iii) the labeled haptens serve well as targets for antieTS-
conjugated QD605 and antieNP-conjugated QD525 anti-
bodies, and also maintain the low background noise. For the
DNP-labeled probe, only DNP-dCTP (with no native dCTP)
was used. For the DIG-labeled probe, a 1:2 ratio of DIG-
dUTP versus native dUTP was used. We did not observe
superior staining with a higher ratio of DIG-dUTP versus
a native dUTP. Similar to our ﬁnding, Ioannou Grifﬁn15
observed no noticeable difference on biotin-labeled probes
with different ratios of biotin-dUTP and unlabeled dUTP.
The facts tell us the importance of empirical optimization on
probe labeling method for each hapten in the context of
QD conjugated anti-hapten antibody ISH assay. With the
knowledge of optimal probe labeling conditions for DNP,761
Table 5 Enumeration of ERG, PTEN, and CEN10 Signals
Instrument Case ID
Original slide
cut no.
Cells
counted
ERG-positive
cells
ERG-positive
cells (%)
Ratio of PTEN/CEN10-
positive signals
1 VR-62-11-24 51 50 1 2 0.94
1 VR-62-11-24 17 50 1 2 0.98
2 VR-62-11-24 4 50 0 0.0 0.97
3 VR-62-11-24 49 50 3 6 0.97
3 VR-62-11-24 11 50 0 0.0 1.00
1 161168T21D 51 50 42 84 0.9
1 161168T21D 21 50 39 78 0.8
3 161168T21D 39 50 40 80 0.9
3 161168T21D 19 50 45 90 0.9
1 VMSI106-C21D 29 50 40 80 0.0
1 VMSI106-C21D 7 50 44 88 0.0
2 VMSI106-C21D 44 50 37 74 0.0
2 VMSI106-C21D 28 50 39 78 0.0
3 VMSI106-C21D 17 50 41 82 0.0
3 VMSI106-C21D 41 50 39 78 0.0
1 VR11-330-4 21 50 0 0.0 1.1
3 VR11-330-4 63 50 1 2 1.1
3 VR11-330-4 39 50 1 2 0.9
VR-62-11-24 and VR11-330-4 are benign prostate tissues. 161168T21D and VMSI106-C21D are prostate cancer cases.
Zhang et alDIG, TS, and NP, this library of four haptens (along with
their respective anti-hapten antibodies) offers us an invalu-
able tool to compose more robust multiplexing ISH assays.
The improved tissue pretreatment condition in the stain-
ing procedure may shed light on the endeavor of over-
coming the lack of reproducibility of QD FISH assays.14,15
After having systemically tested all major components in the
staining procedure with the design of experiment approach,
the pretreatment condition stands out to be the main driver
for robust and reliable QD ISH staining (data not shown).
We rationalize that QDs require more potent tissue per-
meabilization than other ﬂuorophores to achieve optimum
labeling, as they are structurally large particles (>150 kD).
Tholouli et al3 also made a statement that any existing
protocols require optimization on ﬁxation and permeabiliza-
tion for QD application.
Detection of the hapten-labeled nucleotides with their
antibodies conjugated with QDs presented similar challenges
for immunohistochemistry in the past: i) removal of cellular
proteins and nucleic acid associated proteins, ii) retention of
nucleic acids in the tissues, and iii) penetration of labeled
nucleic acid probes and QDs-conjugated antibodies. Chem-
ical and physical pretreatments are the two main approaches,
which are parallel to the antigen retrieval methodologies for
immunohistochemistry.28,29 Although proteinase digestion is
necessary for hybridization of nucleic acids, heat-induced
treatment is usually applied for superior sensitivity and
reproducibility of immunostaining.30 Proteinase K and
pepsin are the most described methods for QD ISH applica-
tion.8,12,31 In addition, Xue et al9 described a combined
approach of heat-induced microwave and proteinase K
treatment for the detection of human papilloma virus 16
and 18 by a biotin-probe with QD-streptavidin in oral squa-
mous cell carcinoma. Moreover, work by Ioannou et al32 on762whole-mount tissue QD ISH provides direct visual evidence
of the levels of QDs tissue penetration on various pretreat-
ments. Proteinase K for 25 minutes (ﬁve time longer than on
a chromogenic ISH) followed with 0.1% Tween 20 signiﬁ-
cantly improved the penetration of QD705-streptavidin,
QD655 anti-ﬂuorescein isothiocyanate, or QD655eanti-
DIG, and resulted in speciﬁc QD staining in deep tissues
(using Biotin-labeled, ﬂuorescein isothiocyanate, and DIG-
labeled RNA probes). The chemical composition of the
buffer and the pH are two key factors to consider when
choosing the heat-induced approach.33 Citrate buffer at
acidic pH and Tris-HCl at basic pH are the most often used
methods. The basic solution seems to be more efﬁcient in
retrieving antigens.34,35 Moreover, a basic buffer containing
EDTA may help antigens return to their native states by
chelating calcium in the cage-like structures formed by the
crosslink of ﬁxatives.36,37 Similarly, our own experience
showed that heating with CC1 (Tris buffer, pH 8.6, 1 mmol/L
EDTA) steps in the current staining procedure signiﬁcantly
improved robustness of the four-color QD ISH assay.
Furthermore, because a low level heavy metal contamination
in formalin solutions during tissue ﬁxation step can cause
partial or total loss of ﬂuorescence,38 1 mmol/L EDTA in
CC1 solution can help prevent the inhibition of QD ﬂuores-
cence by chelating contaminated metals in variously
prepared tissue samples. One may notice the harshness of our
tissue pretreatment condition, which includes two courses of
heating (CC1 at 90C for 92 minutes and CC2 at 82C for 36
minutes) and protease 3 treatment at 37C for 28 minutes.
Although cell and tissue morphology are well accepted on
tested prostate tissues, heat duration and temperature are next
to be considered for optimization.
Finally, the ease of use and reliability of the assay make it
a potential clinical diagnostic tool for evaluating the ERGjmd.amjpathol.org - The Journal of Molecular Diagnostics
Automated Four-Color ERG/PTEN QD FISHand PTEN gene status in prostate cancer. Prostate cancer is
the second most common cancer and the second leading
cause of cancer death in American men. As a slow-growing
disease, some tumors grow so slowly that they would
probably never have led to death or have any symptoms.
Molecular biomarkers that can distinguish indolent from
clinically signiﬁcant prostate cancer would have extremely
high clinical utility, as patients could be stratiﬁed based on
risk assessment. In the past several years, a recurrent fusion
between the androgen regulated gene TMPRSS2 (21q22.3)
and erythroblast transformation-speciﬁc oncogenic tran-
scription factors family member ERG (21q22.2) has been
reported20 to be a common occurrence in prostate carci-
noma. TMPRSS2-ERG has been frequently associated with
more aggressive prostate cancers and a poorer prognosis.17
More recent studies ﬁnd that genomic loss of PTEN and
ERG genetic rearrangements are signiﬁcantly associated
genetic events in human prostate cancer.18,39,40 The two
frequent critical events in human prostate cancer cooperate
to promote tumor development and progression in the pros-
tate.19,41,42 These ﬁndings may imply novel targeted thera-
pies against ERG and PTEN/PI3K/AKT pathway as
preventive and therapeutic approaches in the future. Taken
together, knowledge of ERG and PTEN gene status may
allow more accurate patient stratiﬁcation, prognostication,
and potential targeted therapies.
In summary, the four-color QD ISH assay we developed
on the BenchMark ULTRA is expected to enable multi-
plexing in situ detection of molecular biomarkers in routinely
processed human clinical tissue. First, it allows simultaneous
detection of four genomic targets on a single slide and
therefore increases efﬁciency of the use of a limited amount
of tissue. Second, it uses routinely available ﬂuorescence
microscopes for signal interpretation, not dependent on
spectral imaging software. Third, the brightness and resis-
tance to photobleaching of QDs make the signals easy to
read. Finally, the full automation of the assay procedure from
baking to counterstaining can be completed within an over-
night shift, and provides consistent and accurate results.
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